Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS2404 in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
NCT07751315Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LUB006 in systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (8 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Safety and tolerability of a single subcutaneous dose at Day 85 and Adverse events of multiple subcutaneous injections at Day 141. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
LUB006
03
Conditions
systemic lupus erythematosus (SLE)primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT07751315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751315.